Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases

JAMA

EMBARGOED FOR RELEASE: 6:35 A.M. ET, FRIDAY, JUNE 5, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the 63rd European Renal Association Congress.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.9923?guestAccessKey=45ba1cd9-3280-445f-878c-1e1585df3fee&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060526

 

About The Study: In this exploratory analysis, treatment with finerenone, a nonsteroidal mineralocorticoid receptor antagonist, slowed kidney function decline, reduced albuminuria, and lowered the risk of kidney failure or substantial loss of kidney function in patients with glomerular diseases. These findings suggest an important role for finerenone in preserving kidney function in this population. 

Corresponding Author: To contact the corresponding author, Brendon L. Neuen, MBBS, MSc, PhD, email bneuen@georgeinstitute.org.au.

 

(doi:10.1001/jama.2026.9923)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Defining Prenatal Care Surveillance Metrics Using Electronic Health Record Data

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2026.1295?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=060526

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

Enrollment Assister Perspectives of a Private Health Insurance Program for Undocumented Immigrants

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2026.1514?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=060526

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

Child Welfare Involvement and Health Outcomes in Infants With Prenatal Substance Exposure

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2026.1302?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=060526

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

Patient Experiences With GLP-1 Receptor Agonists

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, JUNE 5, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.16951?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060526

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: In this qualitative study of patient experiences with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), participants described GLP-1 RA therapy functioning as a facilitator rather than a replacement for lifestyle change, emphasizing the need for behavioral interventions alongside pharmacotherapy to sustain treatment benefits. Quality of care was highly variable; thus, standardized guidelines for patient education and clinical support could improve expectation management around likely adverse effects and long-term management.

Corresponding Author: To contact the corresponding author, Isabella de Vere Hunt, MD, email Isabella.deverehunt@phc.ox.ac.uk.

 

(doi:10.1001/jamanetworkopen.2026.16951)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Maternal RSV Prefusion F Vaccination and Acute Respiratory Illness in Infants

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, JUNE 5, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.16773?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060526

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: Maternal respiratory syncytial virus prefusion F (RSVpreF) vaccination was associated with protection against RSV-associated acute respiratory illness and lower respiratory tract disease hospitalization among infants 90 days or younger. These findings provide early clinical evidence supporting the effectiveness of maternal RSVpreF vaccination in preventing RSV-associated hospitalization in infants.

Corresponding Author: To contact the corresponding author, Anne-Marie Rick, MD, MPH, PhD, email Alejandra Ruiz Leon at ruizleonap@upmc.edu.

 

(doi:10.1001/jamanetworkopen.2026.16596)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Treatment Delays in Early Age–Onset Colorectal Cancer

JAMA Oncology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, JUNE 4, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2026.1335?guestAccessKey=f5cd1af9-6538-4dce-ad8c-b0d7ae27af67&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060426

 

About The Study: In this cross-sectional study, early age–onset colorectal cancer (EOCRC) was associated with improved overall survival compared with average age–onset colorectal cancer; however, treatment delays were independently associated with worse survival among patients with EOCRC. Language barriers could be a potentially modifiable risk factor associated with delayed treatment and may provide an opportunity to improve timely care and outcomes in EOCRC. 

Corresponding Author: To contact the corresponding author, Alex C. Kim, MD, PhD, email alex.kim@utsouthwestern.edu.

 

(doi:10.1001/jamaoncol.2026.1335)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Online Menopause Information–Seeking Search Patterns and Commercial Content Over 2 Decades

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, JUNE 4, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.16596?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060426

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: From 2005 to 2025, the proportion of menopause-related searches that were related to commercial products and services increased by 15 to 20 percentage points in the United Kingdom, Australia, and the United States with no difference in the rate of increase by country. Increases appeared earlier in the U.S., with subsequent convergence across countries over time. These results suggest that individuals may be increasingly seeking nonclinical approaches to managing menopause, not only for symptom relief but also for ongoing guidance, tracking, or support outside traditional clinical encounters.

Corresponding Author: To contact the corresponding author, Francesca R. Farina, PhD, email ffarina@uchicago.edu.

 

(doi:10.1001/jamanetworkopen.2026.16596)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease

JAMA

EMBARGOED FOR RELEASE: 6:45 A.M. ET, THURSDAY, JUNE 4, 2026

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the 63rd European Renal Association Congress.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.9379?guestAccessKey=2ddc7b52-ba7e-456c-b5bc-716fb792a29b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060426

 

About The Study: In patients with advanced chronic kidney disease at high cardiovascular risk, low-dose rivaroxaban did not reduce the risk of a composite cardiovascular outcome. Major bleeding rates were significantly higher in the low-dose rivaroxaban group compared with the placebo group. 

Corresponding Author: To contact the corresponding author, Sunil V. Badve, PhD, email sbadve@georgeinstitute.org.au.

 

(doi:10.1001/jama.2026.9379)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Measured and Estimated Glomerular Filtration Rates and Risk of Adverse Health Outcomes

JAMA

EMBARGOED FOR RELEASE: 6:45 A.M. ET, THURSDAY, JUNE 4, 2026

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the 63rd European Renal Association Congress.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.9639?guestAccessKey=2bc8b5d7-fdc4-4f83-9fed-00816fd204bf&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060426

 

About The Study: Among adults in Sweden, lower measured glomerular filtration rate values were associated with higher rates of all-cause mortality, kidney failure with replacement therapy, hospitalization for heart failure, acute kidney injury, and major adverse cardiovascular events. 

Corresponding Author: To contact the corresponding author, Edouard L. Fu, PhD, email e.l.fu@lumc.nl.

 

(doi:10.1001/jama.2026.9639)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Out-of-Pocket Costs and Health-Related Social Needs Among Households With Children

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, JUNE 3, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.16485?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060326

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: The findings of this cohort study of U.S. households with children suggest that high out-of-pocket medical costs may make it more difficult for households to afford health-related social needs (i.e., accessing food, paying bills, and living in quality housing), potentially contributing to adverse health outcomes.

Corresponding Author: To contact the corresponding author, Michael Caniglia, PhD, MPA, email Michael.caniglia@nationwidechildrens.org.

 

(doi:10.1001/jamanetworkopen.2026.16485)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

What Is Ebola?

JAMA

EMBARGOED FOR RELEASE: 11:05 A.M. ET, WEDNESDAY, JUNE 3, 2026

Media advisory: The full article is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.10847?guestAccessKey=961ff57a-21dd-4d33-b79e-a4325795b404&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060326

 

About The Article: This JAMA Patient Page describes how Ebola is transmitted, how common the infection is and where outbreaks have occurred, risk factors and symptoms, and how it is diagnosed and treated.

 

(doi:10.1001/jama.2026.10847)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Surgeon Social Jet Lag and Patient Risk of Major Adverse Events

JAMA Surgery

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, JUNE 3, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2026.1796?guestAccessKey=258f9246-6451-41bc-ae1c-41be466cd990&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060326

 

About The Study: This study found that patients operated on by surgeons experiencing substantial social jet lag had a higher associated risk of major adverse events. Interventions promoting regular sleep timing and reducing circadian misalignment may improve surgeon burnout and patient safety. Social jet lag reflects the discrepancy between sleep timing on workdays and free days.  

Corresponding Author: To contact the corresponding author, Léa Pascal, MPH, email lea.pascal@chu-lyon.fr.

 

(doi:10.1001/jamasurg.2026.1796)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Statin Use and Survival in Early Breast Cancer According to Different Intrinsic Subtypes

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, JUNE 2, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.16375?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060226

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: In this cohort study of patients with early breast cancer, prediagnostic statin use was not associated with higher survival; however, postdiagnostic statin use was associated with lower all-cause and breast cancer–specific mortality among patients with hormone receptor–positive intrinsic subtypes. These findings suggest that statin therapy may improve survival of patients with early hormone receptor–positive subtypes.

Corresponding Author: To contact the corresponding author, Santeri Palmi, MD, email santeri.palmi@tuni.fi.

 

(doi:10.1001/jamanetworkopen.2026.16375)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Residential and Transplant Center Neighborhood Segregation and Live Donor Liver Transplant

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, JUNE 2, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.16148?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060226

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: In this national cohort study, living in or being wait-listed at transplant centers in high-segregation neighborhoods was associated with lower likelihood of live donor liver transplant (LDLT) access and candidates living in high-segregation neighborhoods with a larger racial and ethnic minority population compared with a larger white population had lower likelihood of LDLT. Investing in high-segregation neighborhoods to address these structural disadvantages may help improve equity in LDLT access.

Corresponding Author: To contact the corresponding author, Alexandra T. Strauss, MD, PhD, MIE, email astraus6@jhmi.edu.

 

(doi:10.1001/jamanetworkopen.2026.16148)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Impact of Population-Based Pathogenic Variant Testing on Risk-Based Breast Screening Recommendations

JAMA Oncology

EMBARGOED FOR RELEASE: 10:45 A.M. (ET), SUNDAY, MAY 31, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the 2026 American Society of Clinical Oncology Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2026.2091?guestAccessKey=3856af02-1e14-467f-878f-88bfc98935a8&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=053126

 

About The Study: In this cohort study, most participants with pathogenic variants (PVs) in breast cancer genes would not have been recommended for high-risk screening based on their clinical or clinical plus polygenic risk. PV testing therefore may identify different subsets of high-risk women than clinical risk factors and polygenic risk scores. These findings highlight the importance of population-based PV testing in risk-based screening. 

Corresponding Author: To contact the corresponding author, Laura J. Esserman, MD, MBA, email laura.esserman@ucsf.edu.

 

(doi:10.1001/jamaoncol.2026.2091)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Fovinaciclib for First-Line Therapy of Advanced Breast Cancer

JAMA Oncology

EMBARGOED FOR RELEASE: 2:30 P.M. (ET), MONDAY, JUNE 1, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the 2026 American Society of Clinical Oncology Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2026.1938?guestAccessKey=0e5d2d89-1a45-417a-9249-c906ea9ab814&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060126

 

About The Study: In this randomized clinical trial, adding fovinaciclib to first-line aromatase inhibitor conferred significant and clinically meaningful progression-free survival benefit and consistent improvements in other efficacy outcomes, along with manageable safety and unaffected quality of life. 

Corresponding Author: To contact the corresponding author, Binghe Xu, MD, PhD, email xubinghe@medmail.com.cn.

 

(doi:10.1001/jamaoncol.2026.1938)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Digital Self-Management of Symptoms and Quality of Life for Patients With Advanced Cancer

JAMA Network Open    

EMBARGOED FOR RELEASE: 12:30 P.M. ET, MONDAY, JUNE 1, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the 2026 American Society of Clinical Oncology Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.15509?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060126

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: In this randomized clinical trial of patients with advanced cancer, an app-facilitated palliative care intervention helped maintain health-related quality of life and self-efficacy and reduced acute care use compared with usual care.

Corresponding Author: To contact the corresponding author, Wing-Lok Chan, MBBS, email winglok@hku.hk.

 

(doi:10.1001/jamanetworkopen.2026.15509)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Conditional Medicaid Expansion and Mental Health Outcomes in Georgia

JAMA Network Open    

EMBARGOED FOR RELEASE: 1:15 P.M. ET, TUESDAY, JUNE 2, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the 2026 AcademyHealth Annual Research Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.13934?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060226

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: In this difference-in-differences analysis of national surveillance data, Georgia’s Pathways to Coverage program was associated with worsening mental health among low-income adults. These findings suggest that conditioning Medicaid eligibility on work or community engagement requirements may create additional barriers to coverage and mental health care access, with potential implications for population health and equity.

Corresponding Author: To contact the corresponding author, Sezen O. Onal, PhD, email Sezen.OzcanOnal@downstate.edu.

 

(doi:10.1001/jamanetworkopen.2026.13934)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer

JAMA

EMBARGOED FOR RELEASE: 2:15 P.M. ET, MONDAY, JUNE 1, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the 2026 American Society of Clinical Oncology Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.8992?guestAccessKey=61a8b5d7-be3b-44df-84c7-9c1d2660be86&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060126

 

About The Study: Adjuvant nivolumab was not associated with improved disease-free survival in patients with resected non–small cell lung cancer without sensitizing epidermal growth factor receptor and anaplastic lymphoma kinase alterations when given after planned adjuvant chemotherapy and/or radiotherapy. 

Corresponding Author: To contact the corresponding author, Jamie E. Chaft, MD, email chaftj@mskcc.org.

 

(doi:10.1001/jama.2026.8992)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

AI Chatbot Use and Disclosure for Mental Health Among US Adolescents and Young Adults

JAMA Pediatrics

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, JUNE 1, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2026.2015?guestAccessKey=913abc03-764d-4eed-ac18-0d1817ff8eb4&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060126

 

About The Study: In this nationally representative survey study of U.S. adolescents and young adults, a fifth reported using AI chatbots for mental health advice. AI chatbots are already embedded in many youths’ mental health information ecosystem, underscoring the need for parents and clinicians to proactively discuss chatbot use to promote safety, appropriate expectations, and linkages to evidence-based care. 

Corresponding Author: To contact the corresponding author, Ryan K. McBain, PhD, MPH, email rmcbain@rand.org.

 

(doi:10.1001/jamapediatrics.2026.2015)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Cancer Diagnostic Delay Rates Associated With a Population-Based Screening Trial Evaluating a Cell-Free DNA Multicancer Early Detection Test

JAMA

EMBARGOED FOR RELEASE: 7 P.M. ET, SATURDAY, MAY 30, 2026

Media advisory: The full study and editorials are linked to this news release. This study is being presented at the 2026 AcademyHealth Annual Research Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.6803?guestAccessKey=bbeb6f0a-1852-48bf-b718-00a96d8ad4fc&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=053026

 

About The Study: Regional participation in a population-based multicancer early detection (MCED) screening trial was associated with a modest increase in diagnostic delay rates for patients referred for suspected head and neck, lung, and upper gastrointestinal cancers. This increase is unlikely to have materially affected interpretation of the MCED screening trial primary findings. Future trials of population-based screening interventions likely to affect demand for limited health care resources should consider monitoring for system-level spillover effects. 

Corresponding Author: To contact the corresponding author, Sean Mann, MSc, email smann@rand.org.

 

(doi:10.1001/jama.2026.6803)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Tort Immunity and Nursing Home Staffing

JAMA Health Forum

EMBARGOED FOR RELEASE: 12:30 P.M. (ET), MONDAY, JUNE 1, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the 2026 AcademyHealth Annual Research Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2026.1534?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=060126

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

 

About The Study: In this cohort study of U.S. nursing homes, the introduction of immunity was associated with decreased overall nursing home staffing and staff per resident time. Registered nurse and licensed practical nurse to patient time was not statistically different. During the COVID-19 pandemic, many states adopted immunity from tort liability for harms to nursing home residents.

Corresponding Author: To contact the corresponding author, David S. Zingmond, MD, PhD, email dzingmond@mednet.ucla.edu.

 

(doi:10.1001/jamahealthforum.2026.1534)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Regulatory Definitions and Classification of Biosimilar Medications Across the 6 Regions of the World Health Organization

JAMA Health Forum

EMBARGOED FOR RELEASE: 11 A.M. (ET), SUNDAY, MAY 31, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the 2026 AcademyHealth Annual Research Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2026.1642?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=053126

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

 

About The Study: This scoping review provides a detailed comparison of biosimilar regulatory guidelines across all World Health Organization regions and identified similarities and differences that may limit the transferability of data between and among countries. These barriers can potentially affect medication availability, price, access, and reimbursement of biosimilars.

Corresponding Author: To contact the corresponding author, Jonathan H. Watanabe, PharmD, MS, PhD, email Jonathan.watanabe@ucsf.edu.

 

(doi:10.1001/jamahealthforum.2026.1642)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Institutional Special Needs Plans and End-of-Life Outcomes for Nursing Home Residents With Dementia

JAMA Health Forum

EMBARGOED FOR RELEASE: 11 A.M. (ET), SUNDAY, MAY 31, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the 2026 AcademyHealth Annual Research Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2026.1649?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=053126

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

 

About The Study: In this retrospective cohort study, Institutional Special Needs Plan (I-SNP) enrollment was associated with significantly fewer hospitalizations for nursing home residents with dementia at the end of life, with effect sizes larger for UnitedHealthcare (UHC) vs non-UHC I-SNPs. Plan maturity and volume are likely important factors impacting success.

Corresponding Author: To contact the corresponding author, Elizabeth M. White, APRN, PhD, email elizabeth_white@brown.edu.

 

(doi:10.1001/jamahealthforum.2026.1649)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Immigration Ban and the US Health Care Workforce

JAMA Network Open    

EMBARGOED FOR RELEASE: 5:15 P.M. ET, SATURDAY, MAY 30, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the 2026 AcademyHealth Annual Research Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.18999?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=053026

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: The numbers of physicians and nurses immigrating from countries with complete immigration bans have significantly increased over the past decade, with these countries contributing nearly 24,000 physicians and 56,000 nurses to the entire U.S. health care workforce in 2023. Communities with physicians and nurses from banned countries were much more likely to experience ongoing health care workforce shortages. The findings of this study suggest that the recent complete immigration ban could reduce the physician and nurse workforce in the U.S. and worsen access to care across already underserved communities.

Corresponding Author: To contact the corresponding author, Hao Yu, PhD, email hao_yu@hphci.harvard.edu.

 

(doi:10.1001/jamanetworkopen.2026.18999)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Patient Digital Engagement With After Visit Summary in Ambulatory Care

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, MAY 28, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.15020?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052826

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: In this cross-sectional study of ambulatory visits, digital after visit summary engagement increased but remained low and was associated with a high time investment for physicians. This inefficiency in postvisit communication emphasizes the need to reconsider such communication, particularly with unmarried males, non-English-speaking populations, and publicly insured populations, and in specialty care settings.

Corresponding Author: To contact the corresponding author, Ryan Thomas Halvorson, MD, email ryan.halvorson@ucsf.edu.

 

(doi:10.1001/jamanetworkopen.2026.15020)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Projected US Cardiovascular Disease Burden From Heat Exposure for Future Greenhouse Gas Scenarios

JAMA Cardiology

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, MAY 27, 2026

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2026.1240?guestAccessKey=c9c399a7-42e0-46ee-90b0-171820b0e4ed&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052726

 

About The Study: The findings from this study project that climate change may substantially increase heat-attributable cardiovascular disease burden across the U.S. by 2050, disproportionately affecting economically vulnerable populations and population aging amplifying this impact. The Pacific Northwest showed highest baseline burden, while Southern and Midwestern states demonstrated steepest projected increases. Heat mitigation must become central to cardiovascular prevention, with targeted interventions prioritizing vulnerable communities. The study analyzed 3,108 U.S. counties from 2010 through 2016 with projections in 2030 and 2050.

Corresponding Authors: To contact the corresponding authors, email Sanjay Rajagopalan, MD, (sanjay.rajagopalan@uhhospitals.org) and Salil V. Deo, MD, PhD, (svd14@case.edu).

 

(doi:10.1001/jamacardio.2026.1240)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Comparative Safety of Robotic-Assisted vs Laparoscopic Cholecystectomy in Contemporary Practice

JAMA Surgery

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, MAY 27, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2026.1585?guestAccessKey=f785a279-1bbe-445d-8456-0b2dae6e5dc0&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052726

 

About The Study: This national analysis of Medicare beneficiaries undergoing cholecystectomy between 2020 and 2023 had 2 principal findings. First, the use of robotic-assisted cholecystectomy continued to increase substantially. Second, despite its growth, robotic-assisted cholecystectomy remained associated with higher risk-adjusted rates of bile duct injury compared with laparoscopic cholecystectomy, while differences in overall complication rates between approaches were small. 

Corresponding Author: To contact the corresponding author, Cody Lendon Mullens, MD, MPH, MS, email codymu@med.umich.edu.

 

(doi:10.1001/jamasurg.2026.1585)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Adverse Pregnancy Outcomes and Sedentary Behavior, Light-Intensity Physical Activity, and Daily Steps

JAMA

EMBARGOED FOR RELEASE: 5:15 P.M. ET, WEDNESDAY, MAY 27, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the 2026 American College of Sports Medicine Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.6986?guestAccessKey=6bb26ffc-81d4-4ec1-91e2-bcc40b18db6b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052726

 

About The Study: Among pregnant individuals, sitting less with greater light-intensity movement and steps was associated with significantly lower risks of adverse pregnancy outcomes. Optimizing lighter-intensity activity patterns should be rigorously tested as a strategy to improve pregnancy health. Adverse pregnancy outcomes affect 1 in 5 pregnancies and include hypertensive disorders of pregnancy, gestational diabetes, preterm birth, and small for gestational age.

Corresponding Author: To contact the corresponding author, Bethany Barone Gibbs, PhD, email bethany.gibbs@hsc.wvu.edu.

 

(doi:10.1001/jama.2026.6986)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Hearing Aids for Adults With Mild to Moderate Hearing Loss

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, MAY 27, 2026

Media advisory: The full article is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.4740?guestAccessKey=8330ca95-94c4-4ffa-8748-5114a9e95771&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052726

 

About The Article: This article discusses hearing aids for adults with mild to moderate hearing loss, including hearing aid function and limitations and prescription vs over-the-counter hearing aid devices. 

Corresponding Author: To contact the corresponding author, Karina De Sousa, PhD, email karina.swanepoel@up.ac.za.

 

(doi:10.1001/jama.2026.4740)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Prevalence of Diagnosed Type 2 Diabetes Among US Children and Adolescents

JAMA Pediatrics

EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, MAY 26, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2026.1539?guestAccessKey=6e5936ab-e69b-4936-a18a-ec8ddcb82dca&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052626

 

About The Study: This nationally representative study estimating type 2 diabetes (T2D) prevalence among U.S. children and adolescents found that the prevalence among those ages 10 to 17 was nearly 4-fold higher than a 2017 estimate among those ages 10 to 19. The substantial increase in prevalence is alarming given T2D’s lifetime risk of debilitating complications and premature deaths.

Corresponding Authors: To contact the corresponding authors, email Wei Bao, MD, PhD, (wbao@ustc.edu.cn) and Guifeng Xu, MD, PhD, (xguifeng365@ustc.edu.cn).

 

(doi:10.1001/jamapediatrics.2026.1539)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Plasma eMTBR-tau243 and %p-tau217 for Biological Staging of Alzheimer Disease

JAMA Neurology

EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, MAY 26, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2026.1405?guestAccessKey=7a4721e2-ae1b-41fb-b272-4ae1ffbdb228&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052626

 

About The Study: A plasma-based staging model using eMTBR-tau243 and %p-tau217 demonstrated strong concordance with positron emission tomography-based staging and clinical severity of Alzheimer disease. Plasma-based staging may provide a scalable, minimally invasive approach to biological stratification of Alzheimer disease, with potential value for treatment selection and clinical trial enrichment.

Corresponding Authors: To contact the corresponding authors, email Gemma Salvado, PhD (gemma.salvado@med.lu.se) and Oskar Hansson, MD, PhD (oskar.hansson@med.lu.se).

 

(doi:10.1001/jamaneurol.2026.1405)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Efficacy and Safety of Ecopipam for Tourette Syndrome

JAMA Neurology

EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, MAY 26, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2026.1431?guestAccessKey=c85179fe-77e7-42fe-943f-751d1bee8c12&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052626

 

About The Study: Among patients with Tourette syndrome, ecopipam, a selective dopamine D1 receptor antagonist, maintained tic suppression and was well tolerated for up to 24 weeks, without clinically significant metabolic or movement disorder adverse effects.

Corresponding Author: To contact the corresponding author, Donald L. Gilbert, MD, MS, email donald.gilbert@cchmc.org.

 

(doi:10.1001/jamaneurol.2026.1431)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Medication and Acute Care Use in Young Adults With Opioid Use Subject to Medicaid Prescription Caps

JAMA Health Forum

EMBARGOED FOR RELEASE: 11 A.M. (ET), FRIDAY, MAY 22, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2026.1187?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=052226

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

 

About The Study: In this cohort study, Medicaid prescription caps were associated with lower overall use of prescription medications and greater frequency of acute care use among young adults with opioid use disorder.

Corresponding Author: To contact the corresponding author, Christopher M. Santostefano, MPH, RN, email christopher_santostefano@brown.edu.

 

(doi:10.1001/jamahealthforum.2026.1187)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Antenatal Opioid Exposure and Cerebral Cortical Maturation in Newborns

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, MAY 22, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.14115?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052226

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: This large, multisite cohort study found that antenatal opioid exposure was associated with impaired cerebral cortical folding in newborns. The extent of cerebral cortical impairment differed based on the opioid type and presence of polysubstance exposure. Continued longitudinal neuroimaging and neurodevelopmental assessments are currently underway to examine the trajectory of brain development and clinical significance of these early cortical changes, potentially informing early interventions to support neurodevelopment in this vulnerable population.

Corresponding Author: To contact the corresponding author, Catherine Limperopoulos, PhD, email climpero@childrensnational.org.

 

(doi:10.1001/jamanetworkopen.2026.14115)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Prostate Cancer Mortality After Relabeling Low-Grade Prostate Cancer as Precancerous

JAMA Oncology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, MAY 21, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2026.1391?guestAccessKey=45a915d2-c5ef-4404-8605-38cd6741508b&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052126

 

About The Study: In this study, dropping the cancer label from grade group (GG)1 prostate disease and redefining GG1 prostate disease as a precancerous lesion led to a net reduction in estimated prostate cancer deaths. Proponents for retaining the cancer label for GG1 prostate disease should argue relabeling would have close to zero effects on screening rates or that other harms outweigh the benefits of reduced prostate cancer mortality. 

Corresponding Author: To contact the corresponding author, Andrew J. Vickers, PhD, email vickersa@mskcc.org.

 

(doi:10.1001/jamaoncol.2026.1391)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Heart Failure Trajectories After Guideline-Directed Medical Therapy

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, MAY 21, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.13955?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052126

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: The findings of this cohort study underscore a gap between evidence and practice. Two-thirds of patients with newly identified heart failure with reduced ejection fraction did not undergo left ventricular ejection fraction reassessment, limiting opportunities to confirm persistence, evaluate reverse remodeling, and identify candidates for treatment. Receipt of guideline-directed medical therapy was modest across groups, even among patients with persistent heart failure with reduced ejection fraction, who derive the greatest benefit.

Corresponding Author: To contact the corresponding author, Brianna M. Goodwin Cartwright, MS, email briannac@truveta.com.

 

(doi:10.1001/jamanetworkopen.2026.13955)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Hospital and Emergency Department Pediatric Capability, Patient Characteristics, and Radiology Imaging for Children

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, MAY 20, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.13689?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052026

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: In this cohort study of pediatric emergency department visits, increased pediatric capability was not associated with differences in the patterns of imaging utilization by insurance status or race and ethnicity. Additional efforts are needed to ensure that pediatric capability improves quality and equity of care.

Corresponding Author: To contact the corresponding author, Margaret E. Samuels-Kalow, MD, MPhil, MSHP, email msamuels-kalow@mgb.org.

 

(doi:10.1001/jamanetworkopen.2026.13689)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Nationwide Implementation of Multimodal Prehabilitation and Complications After Colorectal Cancer Surgery

JAMA Surgery

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, MAY 20, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2026.1519?guestAccessKey=f2ae35ad-6bec-4abd-aaf8-5e097a8c9f26&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052026

 

About The Study: The results of this cohort study show that implementation of a uniform multimodal prehabilitation program for unselected patients undergoing colorectal cancer surgery was associated with reduced complication rates and length of hospital stay across all age and American Society of Anesthesiologists score subgroups. 

Corresponding Author: To contact the corresponding author, Gerrit D. Slooter, MD, PhD, email g.slooter@mmc.nl.

 

(doi:10.1001/jamasurg.2026.1519)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Interleukin 6 as a Treatment Target for Depression

JAMA Psychiatry

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, MAY 20, 2026

Media advisory: The full study is linked to this news release. 

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2026.1053?guestAccessKey=b62cde62-853f-4f80-a300-55745bef474a&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052026

 

About The Study: This proof-of-concept randomized clinical trial provides insights into the therapeutic potential of interleukin 6 (IL-6) or IL-6 receptor inhibition for depression and highlights suitable patient selection methods. Interleukin 6, a keystone inflammatory cytokine, is a credible mechanistic candidate for causing depression. 

Corresponding Authors: To contact the corresponding authors, email Éimear M. Foley, PhD (eimear.foley@bristol.ac.uk) and Golam M. Khandaker, PhD, (golam.khandaker@bristol.ac.uk).

 

(10.1001/jamapsychiatry.2026.1053)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Weight Loss in Older Patients With Persistent Atrial Fibrillation

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, MAY 20, 2026

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.5787?guestAccessKey=1d43f9b4-9d6e-4cf8-ac42-715b31607042&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052026

 

About The Study: In older patients with overweight and persistent atrial fibrillation, a low-calorie diet and behavioral support program was associated with significant weight loss at 8 months with no safety concerns but did not affect atrial fibrillation symptoms, atrial fibrillation burden, cardiac remodeling, or the need for further rhythm control interventions.

Corresponding Author: To contact the corresponding author, Rohan Wijesurendra, MB, BChir, DPhil, email rohan.wijesurendra@ndph.ox.ac.uk.

 

(doi:10.1001/jama.2026.5787)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Cognitive Trajectories and Subsequent Accelerometer-Measured Movement Behavior in Older Adults

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, MAY 19, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.13399?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051926

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: In this cohort study of older adults, participants with less favorable long-term memory trajectories were subsequently less active and more sedentary, suggesting that later-life activity patterns may partly reflect cognitive change.

Corresponding Author: To contact the corresponding author, Mikaela Bloomberg, PhD, email mikaela.bloomberg.19@ucl.ac.uk.

 

(doi:10.1001/jamanetworkopen.2026.13399)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Life Expectancy in Chronic Obstructive Pulmonary Disease

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 9:25 A.M. (ET), SUNDAY, MAY 17, 2026

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the American Thoracic Society 2026 International Conference. 

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2026.0207?guestAccessKey=f41c3b9b-5b77-429e-aeec-bf69a05ba129&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051726

 

About The Study: In this cohort study, chronic obstructive pulmonary disease (COPD) was associated with lower life expectancy, including in adults who never smoked. 

Corresponding Authors: To contact the corresponding authors, email Surya P. Bhatt, MD, MSPH, (sbhatt@uabmc.edu) and Elizabeth C. Oelsner, MD, DrPH, (eco7@cumc.columbia.edu).

 

(doi:10.1001/jamainternmed.2026.0207)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Smartphone Use on School Nights in the Adolescent Brain Cognitive Development Study

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2026.1707?guestAccessKey=4122c6c3-eca9-4ba4-a326-9a16d86a8a92&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051826

Studies Being Presented at the American Thoracic Society 2026 International Conference

JAMA

EMBARGOED FOR RELEASE: 2:15 P.M. ET, MONDAY, MAY 18, 2026

Media advisory: The full studies and editorial are linked to this news release. These studies are being presented at the American Thoracic Society 2026 International Conference.

Remote Multicomponent Rehabilitation in Intensive Care Unit Survivors

A 6-week, multicomponent, rehabilitation program did not improve health-related quality of life at 8 weeks after discharge in ICU survivors who required mechanical ventilation. 

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.7401?guestAccessKey=d5b00e3e-6546-422b-b170-7f9751a5f648&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051826

 

# # #

 

4% Tetrasodium EDTA to Prevent Central Venous Access Device–Associated Complications

In an adult critical care setting, use of 4% tetrasodium EDTA (a potent anticoagulant, antimicrobial, and antibiofilm agent) as a locking fluid reduced a composite outcome of central venous access device complications compared with control.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.6025?guestAccessKey=8779014b-32fb-425b-bb86-4d10751eb4ba&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051826

 

Editor’s Note: Please see the articles for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Studies Being Presented at the American Thoracic Society 2026 International Conference

JAMA

EMBARGOED FOR RELEASE: 11:15 A.M. ET, MONDAY, MAY 18, 2026

Media advisory: The full studies are linked to this news release. These studies are being presented at the American Thoracic Society 2026 International Conference.

Biomarker-Based Eligibility for Lung Cancer Screening

Compared with questionnaire-based approaches, the protein-based INTEGRAL-Risk model improved short-term prediction of lung cancer in people with a smoking history. This model has potential to improve selection of high-risk individuals who are most likely to benefit from lung cancer screening.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.8044?guestAccessKey=0eae2f18-12f7-4159-8985-b66ab1adad7a&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051826

 

# # #

 

Cryobiopsy vs Forceps for Bronchoscopic Lung Biopsy

Transbronchial lung biopsy performed with a 1.1-mm cryoprobe had a significantly higher diagnostic yield compared with 2.0-mm forceps in a group of patients with lung nodules or masses, lung transplant, and diffuse parenchymal lung disease.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.7908?guestAccessKey=98bf13bc-cae8-472b-8028-0d59c8856bcf&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051826

 

Editor’s Note: Please see the articles for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Disparities in Inhaler Utilization Among US Adults With Asthma

This study is being published to coincide with the American Thoracic Society 2026 International Conference

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.7613?guestAccessKey=2e69ddd0-1169-4e3a-a4c1-87ea3a04cb1e&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051826

An AI–Enabled Cardiopulmonary Resuscitation Instructor

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, MAY 18, 2026

Media advisory: The full study and editor’s note are linked to this news release.  

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2026.1552?guestAccessKey=bb1c143e-d5c9-4ec1-b89f-3dc073892f2b&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051826

 

About The Study: The findings of this study suggest that AI-enabled cardiopulmonary resuscitation (CPR) instruction shows promise for supporting bystanders. Further validation in diverse, general population settings is warranted to define the role of AI-based CPR instruction as a scalable public health intervention for out-of-hospital cardiac arrests. 

Corresponding Author: To contact the corresponding author, John W. Ayers, PhD, MA, email ayers.john.w@gmail.com.

 

(doi:10.1001/jamainternmed.2026.1552)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Amateur Soccer Heading and Acute Elevations in Blood-Based p-Tau217 and S100B

JAMA Neurology

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, MAY 18, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2026.1224?guestAccessKey=b9a4865f-e420-4d12-adfc-22347d416678&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051826

 

About The Study: The findings of this case-control study show that soccer heading was associated with acute increases in blood biomarkers of neural damage, including dose-response relationships. These findings suggest that amateur-level heading may acutely affect neural integrity.

Corresponding Author: To contact the corresponding author, Marsh Konigs, PhD, email m.konigs@amsterdamumc.nl.

 

(doi:10.1001/jamaneurol.2026.1224)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Dual Immunization Against RSV With RSVpreF and Nirsevimab

JAMA Pediatrics

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, MAY 18, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2026.1346?guestAccessKey=e2814820-b22a-4ec5-9158-da67534c2541&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051826

 

About The Study: This cohort study describes respiratory syncytial virus (RSV)-associated lower respiratory tract infection hospitalizations among infants in France who received both maternal RSVpreF vaccination and nirsevimab during the 2024-2025 RSV season. 

Corresponding Author: To contact the corresponding author, Ludovic Tréluyer, MD, PhD, email ludovic.treluyer@ansm.sante.fr.

 

(doi:10.1001/jamapediatrics.2026.1346)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

High-Dose Vitamin D3 Supplementation During Pregnancy and Test-Based Cognitive Performance at Age 10

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, MAY 18, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.11464?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051826

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: This post hoc analysis of a randomized clinical trial suggests that high-dose vitamin D3 supplementation in pregnancy is positively associated with visual memory, verbal memory, and flexibility or set shift among offspring measured at age 10 years. These findings strengthen evidence on the association of prenatal vitamin D exposure with childhood cognition.

Corresponding Author: To contact the corresponding author, Bo Chawes, MD, PhD, DMSc, email chawes@copsac.com.

 

(doi:10.1001/jamanetworkopen.2026.11464)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, MAY 15, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.12589?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051526

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: In this randomized clinical trial of major depressive disorder, a single dose of psilocybin was associated with rapid antidepressant effects, observed by day 2 and persisting for more than 3 months on secondary outcomes; psilocybin was generally well tolerated, but some individuals required additional support after dosing due to anxiety. These results suggest that psilocybin may provide a rapid and relatively long-lasting antidepressant effect on major depressive disorder, warranting further investigation into repeated dosing or adjunctive treatment strategies.

Corresponding Author: To contact the corresponding author, Hampus Yngwe, MD, MSc, email hampus.yngwe@ki.se.

 

(doi:10.1001/jamanetworkopen.2026.12589)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Armed Conflict and Penetrating Traumatic Brain Injury in Children in the Gaza Strip

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, MAY 15, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.13094?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051526

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: This study assessed functional outcomes at hospital discharge among children and adolescents who sustained penetrating traumatic brain injury (TBI) during armed conflict in the Gaza Strip and found there was substantial morbidity and mortality. Penetrating TBI, characterized by a breach of the dura mater caused by a projectile or fragment, represents one of the most fatal war-related injuries. Survivors frequently endure neurological impairments alongside long-term psychosocial challenges.

Corresponding Author: To contact the corresponding author, Mohammed Asfa, MD, email asfa1991@gmail.com.

 

(doi:10.1001/jamanetworkopen.2026.13094)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Management of Spontaneous Abortion Among Commercially Insured Individuals in the United States After Dobbs v Jackson

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, MAY 18, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.6344?guestAccessKey=59038f2d-d29e-4c32-90dc-1e5e96cf6cc0&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051826

 

About The Study: State-level abortion bans were associated with a shift in spontaneous abortion management away from medication and toward expectant approaches, with persistent reliance on suboptimal misoprostol-only regimens in ban states, suggesting a decrease in management options for individuals with spontaneous abortion in ban states. 

Corresponding Author: To contact the corresponding author, Maria I. Rodriguez, MD, MPH, email rodrigma@ohsu.edu.

 

(doi:10.1001/jama.2026.6344)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Recent COVID-19 Vaccination and Risk of SARS-CoV-2 Transmission

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, MAY 15, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.12609?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051526

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: In this cohort study, recent COVID-19 vaccination was associated with a reduced risk of SARS-CoV-2 transmission. These findings suggest that COVID-19 vaccination may have an indirect benefit of decreasing transmission and thus reducing overall exposure to SARS-CoV-2.

Corresponding Author: To contact the corresponding author, Sarah E. Smith-Jeffcoat, MPH, email uyi7@cdc.gov.

 

(doi:10.1001/jamanetworkopen.2026.12609)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Adverse Pregnancy Outcomes and Cardiovascular Health Among Offspring in Early Adulthood

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, MAY 14, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.6783?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051426

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: In this longitudinal cohort study of mother-child dyads enrolled at the child’s birth, exposure to adverse pregnancy outcomes during gestation, particularly hypertensive disorders of pregnancy, was associated with suboptimal cardiovascular health and arterial injury among offspring in early adulthood. The findings suggest optimizing pregnancy health may support offspring cardiovascular health into early adulthood.

Corresponding Author: To contact the corresponding author, Nilay S. Shah, MD, MPH, email nilay.shah@northwestern.edu.

 

(doi:10.1001/jamanetworkopen.2026.6783)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Exposure to Air Pollutants and Lewy Body and Parkinson Disease–Related Dementias

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, MAY 14, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.12601?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051426

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: In this case-control study, exposures to ambient particulate matter with a diameter less than 2.5 μm or nitrogen dioxide were each associated with increased risks of dementia with Lewy bodies and Parkinson disease–related dementia, with a greater magnitude of association for risk of dementia with Lewy bodies. These findings warrant concern about the impact of air pollution on brain health.

Corresponding Author: To contact the corresponding author, Dimitry S. Davydow, MD, MPH, email ddavydow@ufl.edu.

 

(doi:10.1001/jamanetworkopen.2026.12601)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Trends in Metabolic Bariatric Surgery Utilization in the Era of GLP-1s, 2022-2024

JAMA Surgery

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, MAY 13, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2026.1343?guestAccessKey=bf60d8c4-391f-4322-bfd4-8bc3a52a068a&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051326

 

About The Study: This study found a profound decrease in the utilization of metabolic bariatric surgery, with a 34.1% decrease from 2022 to 2024, while glucagon-like peptide-1 receptor agonist (GLP-1) use increased by 140.4% over the same period. Given the year-on year declines in metabolic bariatric surgery utilization, these trends may continue given the persistent and growing prescribing of GLP-1s. 

Corresponding Author: To contact the corresponding author, Robert J. Calzaretta Jr, MIDS, email robert.calzaretta@analysisgroup.com.

 

(doi:10.1001/jamasurg.2026.1343)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Pragmatic Parental Support to Mitigate Burnout Among Pregnant and Postpartum Trainees

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, MAY 13, 2026

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.5663?guestAccessKey=cc52f287-8aca-4724-81c0-dbf5048e1a4d&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051326

 

About The Study: Occupational burnout threatens care quality, workforce retention, and physician health. In this study, a parental support package significantly mitigated postpartum burnout among childbearing physicians in training.

Corresponding Author: To contact the corresponding author, Erika L. Rangel, MD, MS, email erangel@mgh.harvard.edu.

 

(doi:10.1001/jama.2026.5663)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Firearm Storage in Households With Children

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, MAY 12, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.12191?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051226

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: In this survey study of adult firearm owners who lived in households with children younger than 18 years, more than 1 in 5 reported that at least 1 firearm in their household was both loaded and unlocked, a practice more common when all children in the household were teenagers. More effective approaches to motivating parents to make their firearms inaccessible to both their teenagers and their younger children are needed.

Corresponding Author: To contact the corresponding author, Matthew Miller, MD, MPH, ScD, email ma.miller@northeastern.edu.

 

(doi:10.1001/jamanetworkopen.2026.12191)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Stage IV Breast Cancer Incidence and Survival, 2010-2021

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, MAY 12, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.12042?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051226

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: In this cohort study of individuals with stage IV breast cancer, incidence increased significantly overall, across ages, and for both sexes from 2010 through 2021. The percentage of individuals with stage IV vs stages I to III diagnoses also increased. Although overall survival improved, research is warranted to determine factors contributing to increased incidence, including potential changes in natural history of breast cancer, disease screening, and incidence and mortality of other conditions.

Corresponding Author: To contact the corresponding author, Jose P. Leone, MD, email josep_leone@dfci.harvard.edu.

 

(doi:10.1001/jamanetworkopen.2026.12042)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Ivermectin-Benzimidazole Prescribing Following Celebrity Endorsement

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, MAY 12, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.16780?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051226

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: Ivermectin-benzimidazole prescribing rose rapidly following celebrity endorsement in January 2025, with disproportionate increases among male patients, white patients, residents of the U.S. South, and individuals with cancer. The elevated prescribing observed among patients with cancer is particularly concerning; individuals facing life-threatening illness may delay or forgo conventional treatments in favor of unproven therapies, potentially allowing their disease to progress.

Corresponding Author: To contact the corresponding author, Michelle S. Rockwell, PhD, email msrock@vt.edu.

 

(doi:10.1001/jamanetworkopen.2026.16780)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

State-Level Differences in HPV Vaccine Uptake Among 13- to 17-Year-Old Adolescents

JAMA Pediatrics

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, MAY 11, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2026.1338?guestAccessKey=27364266-7508-4b0d-974b-c5adf2563386&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051126

 

About The Study: This cross-sectional study demonstrates substantial state-level variation in human papillomavirus (HPV) vaccine uptake among U.S. adolescents, even after adjustment for key sociodemographic factors. Several Northeastern states, including Massachusetts, Rhode Island, and New Hampshire, exhibited significantly higher odds of HPV vaccination compared with the reference state, Alabama, whereas multiple Southern states, particularly Mississippi, Georgia, Oklahoma, Kentucky, and West Virginia had significantly lower odds of uptake. 

Corresponding Author: To contact the corresponding author, Chinenye Lynette Ejezie, PhD, MPH, email cejezie@towson.edu.

 

(doi:10.1001/jamapediatrics.2026.1338)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, MAY 11, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.12133?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051126

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

About The Study: In this cohort study of patients with breast cancer, findings suggested a potential association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and improved outcomes among patients with breast cancer who have obesity and related metabolic conditions. These findings support further evaluation of GLP-1 RA therapy in randomized clinical trials.

Corresponding Author: To contact the corresponding author, Bernard F. Fuemmeler, PhD, MPH, email bernard.fuemmeler@vcuhealth.org.

 

(doi:10.1001/jamanetworkopen.2026.12133)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Telemedicine Adoption, US Ambulatory Visits, and Total Medical Spending, 2019-2023

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, MAY 11, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.11835?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051126

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: Nationwide telemedicine adoption was not significantly associated with changes in visits or spending, either overall or when stratified by urbanicity, payer type, or area-level social vulnerability, thus easing concerns about large utilization and spending increases from telemedicine expansion.

Corresponding Author: To contact the corresponding author, John N. Mafi, MD, MPH, email jmafi@mednet.ucla.edu.

 

(doi:10.1001/jamanetworkopen.2026.11835)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Digoxin in Patients With Symptomatic Rheumatic Heart Disease

JAMA

EMBARGOED FOR RELEASE: 7:25 A.M. ET, SUNDAY, MAY 10, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.7335?guestAccessKey=d4c39490-13af-453e-a188-9ccefd58b4a9&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051026

 

About The Study: In patients with symptomatic rheumatic heart disease, digoxin reduced the risk of a composite of all-cause death or new-onset or worsening heart failure, with little risk of toxicity. This study is being published to coincide with the European Society of Cardiology Heart Failure 2026 Congress.

Corresponding Author: To contact the corresponding author, Ganesan Karthikeyan, MD, DM, MSc, email karthik2010@gmail.com.

 

(doi:10.1001/jama.2026.7335)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Efficacy and Safety of Digitalis Glycosides in Heart Failure

JAMA

EMBARGOED FOR RELEASE: 7:25 A.M. ET, SUNDAY, MAY 10, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the European Society of Cardiology Heart Failure 2026 Congress.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.7886?guestAccessKey=4af5df2f-e71c-484b-8b59-1e181b305daf&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051026

 

About The Study: Treatment with digitalis glycosides was associated with a lower risk of the composite of cardiovascular death or first worsening heart failure (HF) event in patients
with heart failure with mildly reduced ejection fraction (HFmrEF) or heart failure with reduced ejection fraction (HFrEF), mainly through a lower risk of worsening HF events. There was no statistically significant interaction with important study characteristics, including the extent
of HF background therapy or type of digitalis glycosides treatment. These results suggest digitalis glycosides may be used as additional medical therapy to reduce worsening HF events in patients with HFmrEF or HFrEF.

Corresponding Author: To contact the corresponding author, Kevin Damman, MD, PhD, email k.damman@umcg.nl.

 

(doi:10.1001/jama.2026.7886)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Rates of Systemic Treatment for Metastatic Non-Small Cell Lung Cancer Among Older Adults

JAMA Oncology  

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, MAY 7, 2026

 

Media advisory: The full study is linked to this news release.
Copy to Clipboard: Embed this link into stories to eliminate the paywall for readers. This predictive link will go live at embargo time.
About The Journal: 
JAMA Oncology is an online-only peer-reviewed medical journal from the JAMA Network, publishing clinical research and commentary in oncology and related fields.
About The Study:
This population-based cohort study used data from over 250,000 older adults (age 65 and older) diagnosed with metastatic non-small cell lung cancer (mNSCLC) between 2006 and 2021, linked from the US Surveillance, Epidemiology, and End Results (SEER) program and Medicare claims. Researchers found that less than half (46.8%) of these patients ever received systemic therapy—including chemotherapy, immunotherapy, or targeted treatments.
Despite considerable advances in the effectiveness and tolerability of mNSCLC treatments over the past two decades, only minimal improvements in patient treatment rates were seen during the study period. Rates of treatment were found to be strongly associated with key factors: survival beyond 90 days after diagnosis, having an oncologist referral, certain cancer histology (such as adenocarcinoma), lower burden of comorbidities, and being married.
Disparities based on sociodemographic factors persisted. Treatment was less likely for Black and Hispanic patients, those residing in rural areas, and those over 80 years old. Even among patients with favorable clinical profiles (age under 80, three or fewer comorbidities, and surviving at least 90 days after diagnosis), about one-fifth received no systemic therapy at all.
The authors highlight ongoing barriers to care: delays in diagnosis, insufficient referrals, and both patient and clinician perceptions about the value of treating advanced lung cancer. They urge further efforts to improve timely diagnosis, comprehensive biomarker testing, referral to oncology specialists, and interventions targeting social and structural determinants of treatment access.
Corresponding Authors:
Adam H. Fox, MD, MS (foxah@musc.edu)
Gerard A. Silvestri, MD, MS (silvestri@musc.edu)
Both are affiliated with the Medical University of South Carolina.
Additional Co-Author Affiliations:
Baptist Cancer Center (Memphis, TN)
American Cancer Society (Atlanta, GA)
University of Colorado School of Medicine (Aurora, CO)
(doi:10.1001/jamaoncol.2026.1080)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Causes of Excess Deaths in the US Compared With Other High-Income Countries

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, MAY 8, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.6147?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050826

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this repeated cross-sectional study of cross-national mortality, the U.S. had substantially higher death rates than other high-income countries between 1999 and 2022, despite having similar access to advanced medical technology. Many of these excess U.S. deaths could likely be avoided by adopting health and social policies that have benefited other high-income countries. These descriptive findings should be interpreted in light of uncertainty arising from differences in death coding, data completeness, and other aspects of data comparability across countries.

Corresponding Author: To contact the corresponding author, Jacob Bor, PhD, email jbor@bu.edu.

 

(doi:10.1001/jamanetworkopen.2026.6147)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Physician-Reported Safety Outcomes of AI-Generated Hospital Course Summaries

JAMA Network Open    

EMBARGOED FOR RELEASE: 10:45 A.M. ET, FRIDAY, MAY 8, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the 2026 Society of General Internal Medicine Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.16556?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050826

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this study, a large language model-based agentic workflow produced hospital course summaries that were frequently used with minimal risk of harm identified. The intervention was associated with a reduction in physician burnout, supporting the viability of AI summarization to mitigate documentation burden.

Corresponding Author: To contact the corresponding author, Francois Grolleau, MD, PhD, email grolleau@stanford.edu.

 

(doi:10.1001/jamanetworkopen.2026.16556)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Clinical Decision Support for Chronic Kidney Disease in Primary Care

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, MAY 8, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.11112?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050826

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this cluster randomized trial of a clinical decision support system for chronic kidney disease in primary care, both the intervention and control groups demonstrated comparable improvements in 6-month outcomes, with no independent effect of the clinical decision support system detected.

Corresponding Authors: To contact the corresponding authors, email Li Yang, PhD, MD (li.yang@bjmu.edu.cn) and Jicheng Lv, MD (chenglv@263.net).

 

(doi:10.1001/jamanetworkopen.2026.11112)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Edible Cannabis and Pain, Sleep, and Mental Health Management in Older Adults

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, MAY 8, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.11718?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050826

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this qualitative study, older adults were motivated to use cannabis as an alternative approach to address health concerns. These findings highlight the importance of physician awareness of older adults’ motivations and concerns to support informed counseling and resources.

Corresponding Author: To contact the corresponding author, Rebecca K. Delaney, PhD, email rebecca.delaney@hsc.utah.edu.

 

(doi:10.1001/jamanetworkopen.2026.11718)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Bidirectional Association Between Premenstrual Disorders and Psychiatric Disorders

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, MAY 8, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.11765?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050826

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this nationwide cohort study conducted in Sweden, bidirectional associations were found between premenstrual disorders and psychiatric disorders and conditions, highlighting the need for sex- and menstrual cycle–informed care in psychiatry. Further research is needed to understand the underlying mechanisms shared between premenstrual disorders and psychiatric disorders.

Corresponding Authors: To contact the corresponding authors, email Jing Zhou, MD, MSc (jing.zhou@ki.se) and Donghao Lu, MD, PhD (donghao.lu@ki.se).

 

(doi:10.1001/jamanetworkopen.2026.11765)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Intravenous Tenecteplase Prior to Endovascular Treatment for Ischemic Stroke at 4.5 to 24 Hours

JAMA

EMBARGOED FOR RELEASE: 2:48 A.M. ET, FRIDAY, MAY 8, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the European Stroke Organisation Conference.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.4292?guestAccessKey=55e90ce1-5126-451b-9c02-eff8cd69b8b3&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050826

 

About The Study: In patients presenting to endovascular treatment (EVT)-capable centers 4.5 to 24 hours after stroke onset with proximal middle cerebral artery occlusion, intravenous tenecteplase before EVT did not improve clinical outcomes vs EVT alone.

Corresponding Authors: To contact the corresponding authors, email Yongjun Wang, MD, (yongjunwang@ncrcnd.org.cn) and Yunyun Xiong, MD, PhD, (xiongyunyun@bjtth.org).

 

(doi:10.1001/jama.2026.4292)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Intravenous Tirofiban After Tenecteplase in Acute Ischemic Stroke

JAMA

EMBARGOED FOR RELEASE: 6:05 A.M. ET, FRIDAY, MAY 8, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the European Stroke Organisation Conference.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.5245?guestAccessKey=eeb07c9c-4836-4408-82a4-2328958d214b&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050826

 

About The Study: Among patients with acute ischemic stroke without large or medium vessel occlusion or a cardioembolic source who had an inadequate clinical response to intravenous tenecteplase, adjunctive intravenous tirofiban increased the likelihood of an excellent outcome at 90 days.

Corresponding Authors: To contact the corresponding authors, email Guoyong Zeng, MD, (hsyygy@163.com) and Zhongming Qiu, MD, (qiuzhongmingdoctor@163.com).

 

(doi:10.1001/jama.2026.5245)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Cash Transfers in the Perinatal Period and Investigations of Infant Maltreatment

JAMA Pediatrics

EMBARGOED FOR RELEASE: 5:30 P.M. (ET), THURSDAY, MAY 7, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the 2026 Society of General Internal Medicine Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2026.1602?guestAccessKey=52646ed2-1a65-46bf-855f-fe86b66ab60e&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050726

 

About The Study: In this study, the Rx Kids prenatal and infant cash prescription program was associated with a significant reduction in investigated allegations of maltreatment among infants. These findings provide important evidence about the role of economic stability in preventing child welfare system involvement. 

Corresponding Author: To contact the corresponding author, Sumit Agarwal, MD, MPH, PhD, email sumitag@umich.edu.

 

(doi:10.1001/jamapediatrics.2026.1602)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

One-Year Mortality Among Opioid Overdose Survivors

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, MAY 7, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.6469?guestAccessKey=b3497bb7-2d30-4a9c-a776-24384e38947b&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050726

 

About The Study: In this population-based cohort, 1-year mortality after an emergency department visit for an opioid overdose was 8.6%, and 21.2% of individuals experienced a repeat opioid overdose. Mortality was higher than estimates from previous research conducted prior to the widespread availability of fentanyl (5.3%-5.5%), although differences in cohort definitions may contribute.

Corresponding Author: To contact the corresponding author, Robert A. Kleinman, MD, MSc, email robert.kleinman@camh.ca.

 

(doi:10.1001/jama.2026.6469)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Psilocybin in the Treatment of Cocaine Use Disorder

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, MAY 7, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.11029?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050726

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this randomized clinical trial, psilocybin appeared to be safe and efficacious for treating cocaine use disorder among individuals from underrepresented and vulnerable populations. Further research is warranted to replicate and expand these findings.

Corresponding Author: To contact the corresponding author, Peter S. Hendricks, PhD, email pshendricks@uabmc.edu.

 

(doi:10.1001/jamanetworkopen.2026.11029)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Cost-Effectiveness of the START Hospital Addiction Consultation Service for Opioid Use Disorder Treatment

JAMA Network Open    

EMBARGOED FOR RELEASE: 8:45 A.M. ET, THURSDAY, MAY 7, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the 2026 Society of General Internal Medicine Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.11324?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050726

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this trial-based economic evaluation, Substance Use Treatment and Recovery Team (START; a hospital-based addiction consultation service) was a cost-effective approach for addressing opioid use disorder (OUD) in the inpatient setting by increasing the initiation of medication for OUD and linkage to OUD-focused care after discharge.

Corresponding Author: To contact the corresponding author, Adeyemi Okunogbe, MBChB, PhD, email yemiokunogbe@gmail.com.

 

(doi:10.1001/jamanetworkopen.2026.11324)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Ketamine Infusions and Rapid Reduction of Suicidal and Depressive Symptoms in Major Depressive Episode

JAMA Psychiatry

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, MAY 6, 2026

Media advisory: The full study is linked to this news release. 

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2026.0612?guestAccessKey=9236a84f-2489-4771-933e-3fdc5da10068&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050626

 

About The Study: The findings of this systematic review and meta-analysis suggest that single and repeated intravenous ketamine infusions are efficacious in reducing suicidal and depressive symptoms in patients with a major depressive episode in the acute phase, while longer-term outcomes are not well established. 

Corresponding Author: To contact the corresponding author, Taeho Greg Rhee, PhD, email tgrhee.research@gmail.com.

 

(10.1001/jamapsychiatry.2026.0612)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Genotype-Guided Antidepressant Prescribing for Patients With Depression

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, MAY 6, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.10609?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050626

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this randomized clinical trial, genotype-guided prescribing of selective serotonin reuptake inhibitors (SSRIs) did not improve control of depression symptoms at 3 months compared with usual care but was associated with higher depression remission rates at 6 months. These findings suggest a possible longer-term clinical benefit and indicate that future studies should focus on the durability and long-term impact of genotype-guided prescribing in the management of depressive symptoms.

Corresponding Author: To contact the corresponding author, Josh F. Peterson, MD, MPH, email josh.peterson@vumc.org.

 

(doi:10.1001/jamanetworkopen.2026.10609)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Adjunctive Antipsychotics in Major Depressive Disorder

JAMA Psychiatry

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, MAY 6, 2026

Media advisory: The full study is linked to this news release. 

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2026.0658?guestAccessKey=5b9e80c8-b2e8-4629-bac1-1421adf9962c&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050626

 

About The Study: This systematic review and meta-analysis indicates that differences exist between adjunctive atypical antipsychotics in the treatment of major depressive disorder with respect to overall efficacy and acceptability, which should be simultaneously considered. The absence of adequate and well-controlled studies documenting maintenance efficacy of adjunctive atypical antipsychotics in major depressive disorder remains a knowledge gap. 

Corresponding Author: To contact the corresponding author, Roger S. McIntrye, MD, email roger.mcintyre@bcdf.org.

 

(10.1001/jamapsychiatry.2026.0658)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Workforce and Staffing at 988 Suicide & Crisis Lifeline Centers

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, MAY 5, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.10789?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050526

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this cross-sectional survey study of 988 Lifeline leaders, results suggested that most centers struggled to find resources to keep the center fully staffed. If staffing challenges persist, centers could face risks to staff well-being and service quality. Financing and operational strategies that support recruitment and retention will be critical to sustaining the quality and accessibility of 988 Lifeline centers.

Corresponding Author: To contact the corresponding author, Samantha Matthews, MPhil, MPA, email smatthew@rand.org.

 

(doi:10.1001/jamanetworkopen.2026.10789)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Outcomes Associated With Hospital at Home vs Traditional Inpatient Stay

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, MAY 5, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.10810?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050526

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this retrospective comparative effectiveness research study of Medicare beneficiaries, hospital at home was associated with lower in-hospital mortality and emergency department use within 30 days of discharge, but not hospital readmissions within 30 days, compared with traditional inpatient care. These findings support hospital at home as an approach that may maintain similar or better short-term outcomes among appropriately selected patients; future studies should evaluate implementation and equity.

Corresponding Author: To contact the corresponding author, J. Priyanka Vakkalanka, PhD, email priyanka-vakkalanka@uiowa.edu.

 

(doi:10.1001/jamanetworkopen.2026.10810)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Individual Profound Autism Criteria and Unmet Needs Among Autistic Adolescents and Their Caregivers

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2026.1087?guestAccessKey=2844fd82-cb89-464e-b52c-e255fa4b28c6&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050426

Daily Living Skill Profiles in Adolescents With Autism and Developmental Disabilities

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2026.1306?guestAccessKey=9f587710-eda0-4880-8d7c-b83fb7fbc34c&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050426

I’m Concerned About Anxiety—What Do I Need to Know?

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, MAY 4, 2026

Media advisory: The full Patient Page is linked to this news release.  

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2026.0392?guestAccessKey=8f26cf74-5b47-422c-b2b8-59f760f26d1b&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050426

 

About The Article: This JAMA Internal Medicine Patient Page discusses different types of anxiety disorders, how they are diagnosed, and how they can be treated.

 

(doi:10.1001/jamainternmed.2026.0392)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Treatment of Anxiety for Adults in Primary Care Settings

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, MAY 4, 2026

Media advisory: The full study is linked to this news release.  

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2026.0395?guestAccessKey=2cc7291e-7fde-4d50-87b0-3c2546419cb1&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050426

 

About The Study: Clinicians should recognize common anxiety presentations and understand how to differentiate between anxiety and other psychiatric or medical conditions. Referring patients to behavioral health specialists for cognitive-behavioral therapy and/or prescribing recommended pharmacotherapy with Collaborative Care Management can help to reduce patient morbidity and improve functioning. 

Corresponding Author: To contact the corresponding author, Robyn L. Shepardson, PhD, email robyn.shepardson@va.gov.

 

(doi:10.1001/jamainternmed.2026.0395)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Cognitive Decline and Household Firearm Storage Among Older Adults

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, MAY 4, 2026

Media advisory: The full study and commentary are linked to this news release.  

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2026.0505?guestAccessKey=69f366a4-cab2-4659-9a08-2cfb54e0c79d&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050426

 

About The Study: This study found that unsecure firearm storage was more common among those with subjective cognitive decline than among those without, although this observation may be driven by differences in storage status by sex, age, veteran status, and presence of children in the home. Existing clinical guidance recommends assessing firearm access and promoting secure storage for patients with cognitive symptoms; the results of this study suggest these recommendations are not yet reflected in household practices.

Corresponding Author: To contact the corresponding author, Kelsey M. Conrick, PhD, MPH, email kmc621@uw.edu.

 

(doi:10.1001/jamainternmed.2026.0505)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Hospital-Based Shootings in the US, 2000-2024

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, MAY 4, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.10552?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050426

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: This systematic review found that hospital-based shootings in the U.S. have increased steadily over the past 25 years, representing an intersection between broader national trends in workplace and firearm violence. Large hospitals, those in the U.S. South, and hospitals in urban communities are particularly at-risk settings. These findings underscore the need for hospital-specific prevention strategies, including consideration of weapons screening technology, alongside broader societal efforts to address rising firearm violence.

Corresponding Author: To contact the corresponding author, Sarayna S. McGuire, MD, MS, email McGuire.Sarayna@mayo.edu.

 

(doi:10.1001/jamanetworkopen.2026.10552)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Birth After Uterus Transplant

JAMA

EMBARGOED FOR RELEASE: 10:55 A.M. ET, FRIDAY, MAY 1, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.7351?guestAccessKey=06e7d7dc-29b3-4ef4-a9ec-88fda1b95087&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050126

 

About The Study: This single-center study demonstrates that uterus transplant can result in a live birth for women with absolute uterine factor infertility. These data support the feasibility of uterus transplant in specialized, multidisciplinary centers capable of integrating transplant surgery, reproductive medicine, and maternal fetal care. Ongoing reporting and data sharing will be essential to refine risk estimates and optimize patient counseling as the uterus transplant field continues to mature.

The publication of this study is timed to coincide with the Annual Clinical & Scientific Meeting of the American College of Obstetrics and Gynecology (ACOG), taking place May 1-3 in Washington, DC.

Corresponding Author: To contact the corresponding author, Liza Johannesson, MD, PhD, email liza.johannesson@bswhealth.org.

 

(doi:10.1001/jama.2026.7351)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Housing Insecurity, Incident Geriatric Conditions, and Mortality in Community-Living Older Persons

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, MAY 1, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.9335?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050126

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this cohort study of community-living older U.S. persons, poor housing affordability was associated with higher risks of frailty, disability, dementia, and mortality, and poor housing quality was associated with higher risks of frailty, disability, and mortality. These findings highlight housing insecurity as a clinically relevant social determinant of health among older persons.

Corresponding Author: To contact the corresponding author, Robert D. Becher, MD, MS, email robert.becher@yale.edu.

 

(doi:10.1001/jamanetworkopen.2026.9335)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

International Availability and Price of Ultraexpensive Drugs in Medicare Part D

JAMA Network Open    

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, MAY 1, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.10053?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050126

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: Despite rapid expansion of ultraexpensive drugs in Medicare Part D, this cohort study found that availability in comparable economies remains limited, and internationally unavailable products often have higher per-beneficiary spending, underscoring their fiscal significance.

Corresponding Author: To contact the corresponding author, So-Yeon Kang, PhD, MBA, email soyeon.kang@georgetown.edu.

 

(doi:10.1001/jamanetworkopen.2026.10053)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Different Predictors for Components of Spaceflight-Associated Neuro-Ocular Syndrome

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/jamaophthalmol.2026.1054?guestAccessKey=d60f63f9-8db5-4efe-a9ba-9472604b991f&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=043026